Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6087773 | 0.89 | CYSLTR1 (0.52) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089372 | 0.88 | CYSLTR1 (0.62) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6088658 | 0.86 | CYSLTR1 (0.51) | CYSLTR1GPBAR1CYSLTR2PPARGMRGPRX4 | |
| SCHEMBL6088975 | 0.86 | CYSLTR1 (0.46) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6091468 | 0.86 | CYSLTR1 (0.51) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6088899 | 0.84 | GPBAR1 (0.61) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089679 | 0.84 | GPBAR1 (0.43) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089086 | 0.84 | CYSLTR1 (0.51) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL6089419 | 0.84 | CYSLTR1 (0.44) | LMNACYSLTR1CYSLTR2PPARDPPARA | |
| SCHEMBL6089456 | 0.83 | CYSLTR1 (0.54) | CYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |